Red Nucleus (Riverside-backed) Acquires iTakeControl

March 4, 2021

Red Nucleus, a Riverside-backed provider of learning and performance solutions for life sciences, has acquired iTakeControl, a mobile platform that collects patient-reported outcomes and real-world data for virtual and home-based clinical trials. The transaction, announced in March 2021, is an add-on to Riverside’s Red Nucleus platform to expand virtual clinical trial and SaaS capabilities for rare disease and specialty pharma clients.

Buyers
Red Nucleus, The Riverside Company
Targets
iTakeControl
Platforms
Red Nucleus
Location
Pennsylvania, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.